Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Transplant Toxicities

Subsequent malignant neoplasms in pediatric cancer patients treated with and without hematopoietic SCT

Abstract

Pediatric cancer patients are at increased risk of subsequent malignant neoplasms (SMNs). However, little is known about the contribution of hematopoietic SCT (HSCT) to the development of SMNs. The objective of this study was to compare the incidence of SMNs in a population cohort of childhood cancer survivors treated with and without HSCT. A cohort of 7986 children (age 0–14 years) diagnosed with cancer in the province of Ontario, Canada between 1985 and 2009 was identified in POGONIS (Pediatric Oncology Group of Ontario Networked Information System), a population-based active cancer registry, and linked to a clinical HSCT database. Among this cohort, 796 patients had an HSCT as part of their primary treatment. Of the 375 allogeneic HSCT patients, 14 (3.7%) developed a SMN at a median follow-up of 12.3 years (range: 2.0–22.9 years). Of the 421 autologous HSCT patients, 8 (1.9%) developed a SMN at a median of 4.5 years (range: 1.3–14.3 years). Of the 7190 patients who did not receive an HSCT, 160 (2.2%) developed a SMN at a median follow-up of 6.8 years (range: 0.0–24.9 years). The 15-year cumulative incidence of SMN was 3.1% among the allogeneic HSCT group, 2.5% among the autologous group and 2.3% in the non-HSCT group. The cumulative incidence curves for the allogeneic HSCT and non-transplant groups only diverged after ~15 years from primary diagnosis. Our findings further corroborate the observation that children who undergo allogeneic HSCT are at a significantly increased risk of developing SMN compared with pediatric cancer survivors treated without HSCT.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Bhatia S, Davies SM, Scott BK, Pulsipher MA, Hansen JA . NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: etiology and pathogenesis of late effects after HCT performed in childhood—methodologic challenges. Biol Blood Marrow Transplant 2011; 17: 1428–1435.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Bhatia S . Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up. Expert Rev Hematol 2011; 4: 437–452.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Witherspoon RP, Deeg HJ, Storb R . Secondary malignancies after marrow transplantation for leukemia or aplastic anemia. Transplant Sci 1994; 4: 33–41.

    CAS  PubMed  Google Scholar 

  4. Socie G, Curtis RE, Deeg HJ, Sobocinski KA, Filipovich AH, Travis LB et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000; 18: 348–357.

    Article  CAS  PubMed  Google Scholar 

  5. Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM, Sobocinski KA et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 4992–5001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL . New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352–1358.

    Article  PubMed  Google Scholar 

  7. Rizzo JD, Curtis RE, Socie G, Sobocinski KA, Gilbert E, Landgren O et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 1175–1183.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897–904.

    Article  CAS  PubMed  Google Scholar 

  9. Danner-Koptik KE, Majhail NS, Brazauskas R, Wang Z, Buchbinder D, Cahn JY et al. Second malignancies after autologous hematopoietic cell transplantation in children. Bone Marrow Transplant 2013; 48: 363–368.

    Article  CAS  PubMed  Google Scholar 

  10. Marrett LD, Clarke EA, Hatcher J, Weir HK . Epidemiologic research using the Ontario Cancer Registry. Can J Public Health 1986; 77: 79–85.

    PubMed  Google Scholar 

  11. Ontario Cancer Registry—CCO. Cancer Care Ontario 12 A.D. November 20. Available at: https://www.cancercare.on.ca/cms/one.aspx?objectId=121939&contextId=1377 (last accessed 5 December 2014).

  12. Green DM, Nolan VG, Goodman PJ, Whitton JA, Srivastava D, Leisenring WM et al. The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 2014; 61: 53–67.

    Article  CAS  PubMed  Google Scholar 

  13. Statistics Canada. Table 051-0001—Estimates of population, by age group and sex for July 1, Canada, provinces and territories, annual, CANSIM. University of Toronto Data Libraray, 2011.

  14. Statistics Canada. Table 103-0550—Canadian Cancer Registry Database (July 2010 file), CANSIM. University of Toronto Data Libraray, 2011.

  15. Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633–3639.

    CAS  PubMed  Google Scholar 

  16. Bhatia S, Louie AD, Bhatia R, O'donnell MR, Fung H, Kashyap A et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001; 19: 464–471.

    Article  CAS  PubMed  Google Scholar 

  17. Socie G, Baker KS, Bhatia S . Subsequent malignant neoplasms after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: S139–S150.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Forrest DL, Nevill TJ, Naiman SC, Le A, Brockington DA, Barnett MJ et al. Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis. Bone Marrow Transplant 2003; 32: 915–923.

    Article  CAS  PubMed  Google Scholar 

  19. Cohen A, Rovelli A, Merlo DF, van Lint MT, Lanino E, Bresters D et al. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study. J Clin Oncol 2007; 25: 2449–2454.

    Article  PubMed  Google Scholar 

  20. Meadows AT, Friedman DL, Neglia JP, Mertens AC, Donaldson SS, Stovall M et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol 2009; 27: 2356–2362.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Statistics Canada. Table 051-0012—Interprovincial migrants, by age group and sex, Canada, provinces and territories, annual (persons). Statistics Canada 2013. Available at: http://www.statcan.gc.ca/pub/91-215-x/2012000/related-connexes-eng.htm (5 December 2014).

  22. Statistics Canada. Table 051-0001—Estimates of population, by age group and sex for July 1, Canada, provinces and territories, annual (persons unless otherwise noted). Statistics Canada 2013 June 19. Available at: http://www.statcan.gc.ca/pub/91-215-x/2012000/related-connexes-eng.htm (5 December 2014).

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J D Pole.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pole, J., Darmawikarta, D., Gassas, A. et al. Subsequent malignant neoplasms in pediatric cancer patients treated with and without hematopoietic SCT. Bone Marrow Transplant 50, 721–726 (2015). https://doi.org/10.1038/bmt.2015.4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.4

This article is cited by

Search

Quick links